Astria Therapeutics Completes Merger with BioCryst Pharmaceuticals, Initiates Delisting
ATXS has more than doubled off its 52-week low of $3.555 on elevated volume (2.9× avg).
Summary
Astria Therapeutics, Inc. has completed its merger with BioCryst Pharmaceuticals, becoming a wholly-owned subsidiary and initiating the delisting of its common stock from Nasdaq.
Key Events · M&A and Partnerships · ATXS
-
Merger Completion
Astria Therapeutics officially merged with BioCryst Pharmaceuticals, Inc. on January 23, 2026, becoming a wholly-owned subsidiary of BioCryst.
-
Delisting Initiated
The company requested Nasdaq to suspend trading and delist its common stock, effective before the opening of trading on January 23, 2026, and intends to terminate SEC registration.
-
Change in Control and Leadership
All previous directors and executive officers of Astria resigned, replaced by appointees from BioCryst, signifying a complete change in control.
-
Merger Consideration
Astria stockholders received 0.59 shares of BioCryst common stock and $8.55 in cash for each share of Astria common stock.
Analysis · ATXS · Life Sciences
This 8-K filing announces the definitive completion of the merger between Astria Therapeutics and BioCryst Pharmaceuticals, Inc., following stockholder approval on January 21, 2026. As a result, Astria Therapeutics is now a wholly-owned subsidiary of BioCryst, and its common stock will be delisted from Nasdaq. This marks the end of Astria's independent public trading and operations, with all prior directors and executive officers resigning. The transaction was partially financed by a new $400 million term loan facility, for which Astria became a guarantor.
At the time of this filing, ATXS was trading at $12.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $718.1M. The 52-week trading range was $3.56 to $13.29. This filing was assessed with negative market sentiment and an importance score of 10 out of 10.